What BioNTech Reveals About Europe's Missing Deep-Tech Scale-Up Machine
- Jörn Menninger
- 4 hours ago
- 5 min read
Europe is not short of scientific founders or early capital. It is short of the specific combination that produced BioNTech: patient anchor capital plus state co-financing plus a global commercial partner, sustained over a decade, without forcing the founder team to relocate to the US. That combination still exists in DACH only by accident. Until it exists by design, BioNTech remains a one-off rather than a model.
Introduction
Executive summary
Europe has world-class scientific founders, growing early-stage capital, and several sovereign-scale state programs. What it lacks is the engineered overlap of all three at deep-tech scale. BioNTech's success required a specific quintet — scientific founder pair, patient family-office anchor (Strüngmann), German state co-investment (€375 million in 2020 for COVID-19), global commercial partner (Pfizer), and prior cap-table room for a structural second act. Each piece exists somewhere in DACH today; the missing layer is the connective tissue.
Key Takeaways
• Europe has the founders, the labs, and the early capital. It does not yet have the engineered overlap.
• BioNTech's success required a five-piece capital architecture that currently assembles only by exception, not by design.
• State co-financing helped (€375M in 2020) — but only because private patient capital had already validated the platform.
• The DACH ecosystem can manufacture this pattern at scale only if family-office, state, and global-partner capital are pre-aligned for 10-15 year horizons.
• Without architectural change, Europe will keep producing one-off platform companies rather than a repeatable scale-up machine.
The five-piece capital architecture
BioNTech worked because five things lined up — and all five had to be in place for a decade before COVID-19 hit. First, a scientific founder pair with prior exit experience (Şahin and Türeci had built and sold Ganymed Pharmaceuticals before BioNTech). Second, a patient family-office anchor (the Strüngmann brothers). Third, a German state willing to co-invest at scale when the strategic case became clear (€375 million in 2020). Fourth, a global commercial partner with distribution at scale (Pfizer). Fifth, founder cap-table control sufficient to design a second act on their own terms (which the 2026 spin demonstrates).
Each of these exists somewhere in DACH today. Patient family-office capital is plentiful — the Strüngmann brothers, the Hopp family, the Quandts, the Reimanns, dozens more. The German state has scaled deep-tech instruments substantially since 2020 (the Deep Tech & Climate Fund, the High-Tech Gründerfonds, the Sprind agency). Global commercial partners are accessible to mature DACH companies. What is missing is the orchestration: the deliberate alignment of all five for the same 10-15 year horizon at the moment of company formation.
Why the architecture matters more than the money
The DACH funding picture in 2025 is healthier than the regional narrative suggests. Startuprad.io's 2025 funding analysis: https://www.startuprad.io/post/dach-startup-funding-2025-deep-tech-defense-and-decacorns — tracks deep tech, defense, and decacorn-level rounds across the region. The unicorn tracker: https://www.startuprad.io/post/the-ultimate-2025-guide-to-dach-unicorns-startuprad-io-tracker — shows over 45 active unicorns. The capital is present. The problem is not aggregate capital availability; it is whether that capital is structured to match the technology horizon.
BioNTech did not need more capital. It needed capital structured for the right horizon. That distinction is what most European deep-tech policy still misses.
What policy and capital would have to change
Three structural changes would move DACH from accident to architecture. First, family-office capital pools could be deliberately matched to deep-tech founders at incorporation, with explicit 10+ year horizons and structured liquidity windows. Second, state co-investment instruments could pre-commit conditional capital at incorporation rather than reactively. Third, global commercial partner relationships could be intermediated by ecosystem actors with the relationship density to make these introductions before product-market fit, not after.
The cluster's parting question
The BioNTech Founders Cluster started with a single observation: that the company is bigger than the vaccine. It ends with a structural one: that the founder pattern is bigger than BioNTech. Whether the next BioNTech is built by the Strüngmann brothers' next bet, by a coordinated state-private architecture, or by an entirely new orchestrator class is the question the next decade of European deep tech will answer.
The cluster continues this Friday with the Strüngmann Cluster anchor — the family-office capital story underneath this entire pattern.
FAQ
Why is Europe still seen as bad at deep-tech scale-ups?
Because it produces them by exception rather than by design. Each individual European deep-tech success requires an unusual alignment of capital types that does not assemble itself.
What was the role of state funding in BioNTech's success?
Germany committed up to €375 million in 2020 for COVID-19 vaccine development at BioNTech. The state funding was decisive — but it arrived only because private patient capital had already validated the platform over a decade.
What would a deep-tech scale-up machine actually look like?
A coordinated layer in which family-office capital, state co-investment, and global commercial partners pre-align for the same long-horizon founder bet at the moment of incorporation.
People and money behind this story
The five-piece capital architecture this article describes only assembles when four sets of relationships line up — the BioNTech case shows them all at once, which is why it is so rare.
Founders → entity (current and earlier). Uğur Şahin and Özlem Türeci co-founded BioNTech in Mainz in 2008. They had previously co-founded Ganymed Pharmaceuticals in 2001 (acquired by Astellas Pharma in 2016). The earlier company taught the founders how to build a Mainz-based mRNA-adjacent biotech to scale; BioNTech is the second iteration of that playbook.
Co-founders. Şahin and Türeci are married and a single founding unit. Andreas and Thomas Strüngmann are an identical-twin co-founder pair behind Hexal (1986) and Eon Labs (1995). The Hopp family (Dietmar Hopp founded SAP), the Quandt family, and the Klatten branch are additional DACH dynastic family-office co-investor units mentioned in the article — each with its own internal partnership structure.
Investors → investing entity. Andreas and Thomas Strüngmann each act as a co-controller of Athos Service. Bill Gates and Melinda French Gates are the principal founders of the Gates Foundation. Each natural-person investor in the BioNTech story sits behind a clearly named investing vehicle.
Investing entity → portfolio companies. Athos Service holds the BioNTech anchor position (since 2008), plus positions in Immatics and Tubulis. The Gates Foundation invested ~$55M in BioNTech in 2019 for HIV and tuberculosis programs. MIG Capital was an early-stage venture co-investor in BioNTech's pre-IPO rounds. Pfizer is the strategic commercial partner that scaled the COVID-19 vaccine globally. The five-piece pattern this article describes — patient family-office capital, state co-financing, global commercial partner, founder cap-table control, scientific founder pair with prior exit — is exactly the assembly the BioNTech entity graph encodes.
Related on Startuprad.io
If you are a B2B technology company looking to enter or scale in the DACH region, the Startuprad.io network connects you with founders, investors, and strategic partners across Germany, Austria, and Switzerland. Become a partner to access introductions, distribution, and ecosystem visibility.
About the author
Joern "Joe" Menninger is the founder and host of Startuprad.io, the most-syndicated startup podcast covering the DACH region (Germany, Austria, Switzerland). With more than 740 episodes and over 1 million streams, Startuprad.io has hosted founders, investors, and policymakers shaping the European tech ecosystem since 2014. Connect on LinkedIn.
Comments